1Nils Kucher.Recent advances in the diagnosis and treatment of pulmonary thromboembolism.ACC Current Journal Review,2003,12:28-32.
2Becker DM.Venous thromboembolism:epidemiology,diagnosis,prevention.J Gen Intern Med,1986,1:402-411.
3Dalen JE,Paraskos JA,Ockene IS,et al.Venous thromboembolism.Scope of the problem.Chest,1986,89 (Suppl 5):370S-373S.
4Salzman EW,Davies GC.Prophylaxis of venous thromboembolism.An analysis of cost effectiveness.Ann Surg,1980,191:207-218.
5Koopman MM,Bossuyt PM.Low molecular weight heparin for outpatient treatment of venous thromboembolism safe,effective,and cost reducing? Am J Med,2003,115:324-325.
6Kakkar AK.Low-and ultra-low-molecular-weight heparins.Best Prac Res Clin Haematol,2004,17:77-87.
7Luk C,Wells PS,Anderson D,et al.Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy.AmJ Med,2001,111:270-273.
8Pini M,Aiello S,Manotti C,et al.Low-molecular-weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis.Thromb Haemost,1994,72:191-197.
9Lopaciuk S,Bielska-Falda H,Noszczyk W,et al.Low-molecular-weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis.Thromb Haemost,1999,81:26-31.
10Samama MM,Gerotziafas GT.Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux).Thromb Res,2003,109:1-11.
